Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-serine for chronic kidney disease due to hypertensive nephropathy
ChiCTR2400089707Phase 4Not yet recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic kidney disease (CKD) and nephrosclerosis comparing L-serine 100 mg/day with Placebo 100 mg/day (2 arms). Primary endpoint: glomerular filtration rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
l-serine
03
Conditions
chronic kidney disease (CKD)nephrosclerosis
Beyond the preview
Go deeper on ChiCTR2400089707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089707.